Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status

This systematic review and meta-analysis examined the impact of chemoimmunotherapy compared to chemotherapy alone in patients with solid tumors. The analysis included a total sample size of 25915 patients. The population comprised individuals with and without liver metastases. The primary outcome assessed was overall survival, while progression-free survival served as a key secondary outcome. The study setting details were not reported in the provided data. The intervention involved the combination of chemotherapy and an immune checkpoint inhibitor, while the comparator was chemotherapy administered alone. Specific dosing protocols or regimen details were not reported in the input data.

Regarding the primary outcome of overall survival, the pooled interaction hazard ratio was 1.00. The 95% confidence interval for this interaction was 0.91 to 1.09, with a p-value of 0.92. This indicates no statistically significant effect modification by liver metastasis status. Consequently, there was no difference between groups regarding the magnitude of benefit derived from the addition of immunotherapy based on the presence of liver metastases.

When analyzing overall survival specifically in patients with liver metastases, chemoimmunotherapy significantly improved survival outcomes. The effect size for this subgroup was 0.76, with a 95% confidence interval of 0.71 to 0.82. Similarly, in patients without liver metastases, chemoimmunotherapy significantly improved survival. The effect size for this group was also 0.76, with a 95% confidence interval of 0.73 to 0.79. These findings suggest a consistent benefit across the two major subpopulations defined by liver involvement.

For progression-free survival, the pooled interaction hazard ratio was 1.04. The 95% confidence interval ranged from 0.93 to 1.17, and the p-value was 0.49. This result indicates no statistically significant effect modification by liver metastasis status for progression-free survival either. In patients with liver metastases, chemoimmunotherapy significantly improved progression-free survival with an effect size of 0.64 and a 95% confidence interval of 0.58 to 0.71. In patients without liver metastases, the improvement in progression-free survival had an effect size of 0.59, with a 95% confidence interval of 0.56 to 0.63.

Safety and tolerability findings were not reported in the provided data. Adverse events, serious adverse events, discontinuations, and general tolerability metrics were not reported. Therefore, no specific rates or qualitative descriptions of safety profiles can be included in this summary. The limitations of the study were not reported in the input data. Funding sources or conflicts of interest were also not reported.

The clinical implications suggest that chemoimmunotherapy offers a survival benefit for patients with solid tumors irrespective of liver metastasis status. This finding supports the consideration of chemoimmunotherapy in this broad population. However, the lack of reported safety data limits the ability to fully assess the risk-benefit profile for clinicians. Questions remain regarding the specific safety profile of these regimens in patients with liver metastases, as this information was not provided. The certainty of these findings is constrained by the absence of reported safety data and the lack of detailed study settings or funding disclosures. Practitioners should interpret these survival benefits alongside external safety data from primary trials not included in this specific meta-analysis.